15+ years of pharmaceutical industry experience, especially in drug development., Bachelor's degree; advanced degrees like MSc are preferred., Experience leading global, late-stage clinical development programs, including regulatory approvals., Proven ability to communicate effectively across all organizational levels and manage cross-functional teams..
Key responsibilities:
Develop and implement program management strategies aligned with company goals.
Oversee planning, execution, and tracking of multiple clinical development programs.
Manage cross-functional teams to ensure projects stay on schedule and within budget.
Facilitate communication and decision-making among leadership and project teams.
Report this Job
Help us maintain the quality of our job listings. If you find any issues
with this job post, please let us know. Select the reason you're reporting
this job:
Recruiting agency for R&D professionals at early-stage biotechnology companies. We offer full life cycle recruiting, talent acquisition consulting, and recruiting technology implementation.We also built and maintain the only job board specifically for young, small biotech startups.
Prilenia, a private biopharmaceutical company with a highly committed and talented global team, is seeking a SeniorExecutive Director, Program Management located in Europe, Israel or the United States, east coast location is strongly preferred.
Being part of Prilenia is being a part of a simple but urgent mission – the development of transformative medicines for people affected by devastating neurodegenerative diseases. Driven by an unwavering commitment to scientific excellence, Prilenia is developing pridopidine, a firstinclass potentially neuroprotective sigma1 receptor (S1R) agonist, which, if approved by the EMA later this year, could be the first approved drug to impact clinical disease progression and not just manage symptoms.
Prilenia holds Orphan Drug designation for pridopidine in HD and ALS in the U.S. and EU. In addition, pridopidine has received Fast Track designation by the U.S. Food and Drug Administration (FDA) for the treatment of HD. The European Medicines Agency (EMA) has accepted for review Prilenia’s European Marketing Authorisation Application (MAA) seeking regulatory approval of pridopidine for the treatment of HD. This is the first submission seeking approval for a potential treatment that can impact clinical progression in HD. For ALS, Prilenia also plans to initiate a pivotal Phase 3 trial to evaluate pridopidine.
To learn more about our story and company culture, visit us at https:Prilenia.com